H.C. Wainwright raised the firm’s price target on Tango Therapeutics (TNGX) to $27 from $13 and keeps a Buy rating on the shares. The firm upped its probability of approval for vopimetostat to 50% from 30% after the company announce a clinical trial collaboration and supply agreement with Erasca.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNGX:
- Midday Fly By: Stocks tumble as oil prices climb again
- Erasca, Tango Therapeutics enter clinical collaboration, supply agreement
- Tango Therapeutics reports Q4 EPS (29c), consensus (33c)
- Tango Therapeutics weakness an ‘over reaction,’ says Stifel
- Tango Therapeutics initiated with an Outperform at Mizuho